Lonvo-z Reports Durable HAE Attack Reduction
Intellia reports an 89% reduction in hereditary angioedema attacks versus patients’ own baselines for up to four years; randomized HAELO data showed an 87% reduction through week 28. Long-term results are uncontrolled and company-reported, so safety and durability of permanent gene editing remain central; an FDA decision is expected in March 2027.
Sources (2)
Updated Nov 18, 2026